Rezolute Presents Phase 3 SUNRIZE Data for Hyperinsulinism
Rezolute will deliver an oral presentation of Phase 3 results for ersodetug (sunRIZE; RZ358-301) in congenital hyperinsulinism at the...
Pivotal Pancreatic Cancer Trial Results Set for ASCO 2026
Revolution Medicines will take the ASCO Plenary stage on May 31 to unveil full Phase 3 results from RASolute...
Oculis Completes Last Patient Visit in Phase 3 DME Trial
Oculis has completed the final patient visits in both Phase 3 DIAMOND trials of OCS-01, a high-concentration dexamethasone eye...
Atsena’s Retinoschisis Trial Advances to Pivotal Cohort
Atsena Therapeutics has cleared a key gate in its Lighthouse program for X-linked retinoschisis, with an independent data monitoring...
Crexont® Adds 3+ Hours of ‘Good ON’ Time for Parkinson’s
Amneal reported positive interim results from its ongoing Phase 4 ELEVATE-PD switch study, presented at AAN 2026, showing that...
Biogen Inks Deal with TJ Biopharma for Felzartamab in China
Biogen has acquired TJ Biopharma’s exclusive rights to felzartamab in Greater China for $100 million upfront, up to $750...
NRx Welcomes Push for Psychedelic Medication Approval
The White House has issued an executive order to accelerate development and approval pathways for treatments targeting serious mental...
Masitinib Offers Hope for Survival, Quality of Life in ALS
AB Science has posted a medRxiv preprint reporting a substantial survival signal for masitinib in amyotrophic lateral sclerosis, based...
Cell Therapies: A New Horizon for Neural Hearing Loss
Rinri Therapeutics has published a comprehensive review framing neural hearing loss—driven by auditory nerve dysfunction—as a central and underdiagnosed...
BVI’s New Virtuoso® Surgical Platform Earns EU MDR Approval
BVI has secured CE Mark certification under the EU Medical Device Regulation for Virtuoso, a next-generation dual-function surgical platform...